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1. Introduction
Endometrial cancer is a potentially preventable disease but still many new cases occur each
year. In the USA, the incidence of endometrial cancer has increased by more than 30% over
the past 20 years. [1] Globally, about 4% of all cancers in women are endometrial cancers that
occur predominantly in postmenopausal women, although many are now also diagnosed in
younger women. [2] It is the leading gynecological malignancy with approximately 47,130
women diagnosed in 2012 in the USA. [3] Endometrial cancer is often diagnosed at an early
stage due to abnormal vaginal bleeding which occurs as a prominent clinical feature in most
women. Two types of endometrial cancer can be distinguished. Type 1, occurring in approx‐
imately 80% of women, carries a better prognosis, has predominantly endometrioid histology
and is well or moderately differentiated (grading G1-G2), and Type 2 includes worse progno‐
sis, poorly differentiated (grade G3) carcinomas, like serous and clear cell carcinomas. [4] The
epidemiology of Type 1 endometrial cancer is fairly well understood: 1) prolonged unopposed
estrogen exposure is the endocrine background of this hormonally regulated neoplasm; 2)
hereditary factors are associated with an increased risk and high parity and later age at last
birth are protective [5, 6]; 3) the role of obesity as an important risk factor is well established;
4) combined oral contraceptives are protective, whereas 5) hormone replacement therapy
(HRT) in the menopause is an important risk factor and the risk increases markedly with the
use of estrogen only and sequential HRT. Understanding the causative role of these conditions
constitutes the basis for prevention strategies. The rising obesity epidemic and decreased
fertility are likely to result in a higher incidence of endometrial cancer and may become an
important public health problem globally in the coming years. This communication will focus
on the risk groups and will formulate some strategies for the prevention of cancer of the
endometrium in women at increased risk.
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2. Risk factors for endometrial cancer
2.1. Hormone replacement therapy
The primary role of progestin in postmenopausal estrogen therapy is endometrial protection
to prevent hyperplasia. [7] Prior to the widespread use of combined estrogen-progestin
therapy (EPT), the risk of developing hyperplasia due to unopposed estrogen stimulation was
substantial. Endometrial hyperplasia in postmenopausal women with an intact uterus, treated
with unopposed oral estrogen, was found in 20% of women during the first year and in 62%
after 3 years of estrogen therapy (ET). [8] In support of this finding, in the Postmenoapausal
Estrogen/Progestin Intervention Trial, 62% of women who received only estrogen (0.625 mg
of conjugated equine estrogen orally daily) developed endometrial hyperplasia. One third of
these women had complex hyperplasia with or without atypia. [9] Hyperplasia is characterized
by a proliferation of the endometrial glands. In non-atypical hyperplasia, the glands are
outgrown yet normal, but in atypical hyperplasia glandular abnormality is already present
both structurally and at cellular level. [10] Non-atypical hyperplasia rarely progresses to more
severe conditions. Atypical adenomatous hyperplasia, on the other hand, has been observed
to progress to adenocarcinoma of the uterus in 29% of cases. [11]
Progestins should, therefore, be added to ET in all postmenopausal women with an intact
uterus. Since the mid-1980s, EPT has increasingly been prescribed. The North American
Menopause Society reviewed the types of EPT regimen used in the USA and concluded that
standard regimens provide adequate endometrial protection. [7] A Cochrane review devoted
to this subject also came to the conclusion that the addition of an oral progestin to ET, admin‐
istered either continuous cyclic or continuous combined, is associated with reduced rates of
hyperplasia. [12] An important drawback of postmenopausal EPT is the occurrence of
withdrawal or breakthrough bleedings. Withdrawal uterine bleedings occur in 80% of women
using cyclic EPT. Continuous combined regimens avoid withdrawal bleeding, but break‐
through bleeding has been observed in up to 40% of women during the first 6 months. Most
postmenopausal women dislike breakthrough bleedings and this is the most common reason
for discontinuation and non-adherence to the treatment regimen. With EPT, therefore,
irregular bleeding should be kept to a minimum. Depending on the EPT type, dose and route
of administration, progestins may have adverse effects on the cardiovascular system, coagu‐
lation and breast tissue. The Women’s Health Initiative (WHI) reported an increased risk for
heart disease, stroke and breast cancer. [13] Since these adverse effects were not observed with
ET alone, it is speculated that adding progestins may diminish the beneficial effects on
atherosclerosis, vasodilatation and plasma lipids and may contribute to the increased risk of
breast cancer. Indeed, the WHI study suggests that EPT may stimulate breast cancer growth
and hinder breast cancer diagnosis due to increased mammographic density when a progestin
is added to ET. [14, 15] This was confirmed in the Million Women Study and other studies, in
particular a Swedish cohort study. [16, 17, 18]
Intrauterine-administered progestin, such as levonorgestrel (LNG), delivered directly to the
target cells of the endometrium, has a profound suppressive effect on endometrial growth
rendering the endometrium inactive and simultaneously eliminating uterine bleeding. [19,
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20] Pharmacokinetic studies with an intrauterine system (IUS) releasing 20 μg of LNG/day
(Mirena®; Bayer AG, Germany) have shown substantially lower plasma LNG concentrations
than those seen with a subdermal LNG implant (Norplant®; Pfizer Pharmaceuticals Inc, USA),
the combined oral contraceptive pill and the mini-pill; moreover, unlike with oral contracep‐
tives, LNG levels with the Mirena LNG-IUS do not display peaks and troughs. [21] This is
important because the low plasma levels may have a significantly lower impact on organs and
tissues, such as the breast, coagulation system, and cardiovascular system.
Studies conducted by us and by others using continuous combined estrogen plus low-dose
LNG-IUS after 5 years of use in postmenopausal women, provided data on the endometrial
morphology to verify endometrial safety. The main objective of these studies was to evaluate
an alternative route of progestin administration in postmenopausal women using ET. They
suggest that continuous combined ET with intrauterine delivery of a progestin was highly
accepted by the participating women. The rationale of the development of LNG-IUSs specifi‐
cally for postmenopausal women is to minimize the potential adverse systemic effects. As
progestins are required only to oppose the stimulating effects of estrogens on the endometri‐
um, locally acting progestins, by definition, could avoid these unwanted metabolic effects.
Intrauterine LNG delivery with low-dose systems, even though minimal absorption may
occur, should be regarded as essentially locally acting. This regimen also offers important
additional benefits that could be exploited, such as high adherence to treatment and a low
discontinuation rate because of bleeding problems and progestin-like side effects. In addition,
a LNG-IUS that adapts to the decreasing dimensions of the uterus gradually reduced in size
due to the suppressive effect of LNG and the decreasing levels of endogenous estrogen, will
be optimally tolerated by the women. [22, 23]
2.2. Polycystic ovary syndrome
Women with polycystic ovary syndrome (PCOS) are about three times more likely to develop
endometrial cancer compared with women without this condition. [24] PCOS affects approx‐
imately 5 to 10% of women of reproductive age. The disorder is characterized by a disruption
of normal reproductive physiology and should be diagnosed in women with oligomenorrhea
or amenoorrhea, hyperandrogenemia and polycystic ovaries defined by ultrasonography after
exclusion of medical conditions that cause irregular menstrual cycles and androgen excess.
[25] Women with PCOS have a higher prevalence of obesity, impaired glucose tolerance and
type 2 diabetes. They are at risk of cardiovascular disease and often have features of metabolic
syndrome, including hypertension, dyslipidemia, visceral obesity and insulin resistence. [26]
Women with PCOS should, therefore, be screened for type 2 diabetes and for cardiovascular
risk by fasting glucose followed by a glucose tolerance test, BMI, fasting lipid and lipoprotein
levels, and other metabolic syndrome risk factors. The condition that makes PCOS patients
vulnerable to endometrial cancer is chronic anovulation as prolonged exposure to unopposed
estrogen can lead to endometrial hyperplasia and cancer. It is important to identify individuals
at risk at an early stage.
From 2 to 14% of patients diagnosed with endometrial cancer are women younger than 40 and
the diagnosis is typically associated with the detection of an accompanying hyperestrogenic
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state. [25] According to studies in the United States, an estimated prevalence in very young
women is 0.8%. [27, 28] A comprehensive review of PCOS was published by the American
College of Obstetricians and Gynecologists. [29] Of note, PCOS can occur both in normal
weight and overweight women. Yet classically, the young woman with endometrial hyper‐
plasia or cancer is obese and nulliparous but, recently, several studies found up to 50% of
women with endometrial cancer to be slender and with regular menstrual cycles. The pro‐
portion of estrogen and progesterone receptor positivity is similar in both obese and slim
patients. Such women should be evaluated for concurrent ovarian malignancy (see Lynch
syndrome below) which occurs in some studies in approximately 10% of cases. Therefore, 3-
D ultrasound and magnetic resonance imaging (MRI) can be valuable additions in the
diagnosis and staging of these patients.
2.3. Excessive body mass: Overweight and obesity
Obesity has become a major public health problem on a global scale. Overweight and obesity
are not only an established risk factor for cardiovascular disease and type 2 diabetes; they are
also an important risk factor for the development of endometrial cancer. [30] Renehan at al.
found that each increase in BMI of 5 kg/m2 significantly increased a woman’s risk for the
development of endometrial cancer. [31] Estrogen is a known endometrial growth factor in
these women. The excess estrogens originate mostly from the conversion of androstenedione
to estrone and testosterone to estradiol by peripheral adipose tissue. [32] Consequently, in
obese postmenopausal women, adipose tissue becomes the primary source of circulating
estrogen. Concentrations of estrogens in the adipose tissue have been measured at levels
several-fold above that observed in plasma. Also, higher levels of insulin in obese women
contribute to the increased risk for endometrial cancer as insulin demonstrates mitotic and
antiapoptotic activity. Furthermore, serum sex hormone-binding globulin (SHBG) levels
decrease with increasing adiposity, thus rising the fraction of circulating unbound estrogen.
The relationship between obesity and endometrial cancer has been well studied and has been
acknowledged as a risk factor in women over 30 years of age. A strong association between
early age at diagnosis and Type 1 endometrial cancer was found. The relationship was linear,
suggesting that as obesity becomes more severe, the underlying carcinogenic mechanisms are
more vividly activated. [4] There is limited public knowledge of the relationship between
obesity and cancer risk. Making the data available to overweight and obese women could be
useful to inform them about the risks which could affect their lives at an early age, and about
the steps they could undertake to reduce or eliminate this risk, since prevention and other risk
reduction strategies in the obese/overweight female population are possible with a high degree
of success.
2.4. Lynch syndrome
Lynch syndrome is one of the most common cancer predisposition syndromes estimated to
affect as many as 1 in 370 individuals. [33, 34] Often called hereditary nonpolyposis colorectal
cancer it is an inherited disorder that increases the risk of many types of cancer, particularly
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cancers of the colon and rectum, which are collectively referred to as colorectal cancer.
Individuals with Lynch syndrome also have an increased risk for cancers of the stomach, small
intestine, liver, gallbladder ducts, upper urinary tract, brain, and skin. Additionally, women
with this disorder have a high risk for cancer of the ovaries and endometrium. Patients with
Lynch syndrome may occasionally have noncancerous polyps in the colon. For many women
with Lynch syndrome, the risk for endometrial cancer is comparable or even exceeds their risk
for colorectal cancer. In the United States, about 140,000 new cases of colorectal cancer are
diagnosed each year. Approximately 3 to 5 percent of these cancers are caused by Lynch
syndrome. Estimates suggest that as many as 1 in 10 young age (< 50) endometrial cancers are
associated with Lynch syndrome. Broader knowledge of population carrier frequency for
DNA mismatch repair gene mutations could contribute to the understanding of the burden of
cancer due to genetic susceptibility, but robust prevalence estimates are lacking. The lifetime
endometrial cancer risk is between 27% and 71% which exceeds that of colorectal cancer. Mean
age of occurrence is approximately 50 years (62 years in non-Lynch) and 18% are diagnosed
under the age of 40 years. Practical guidelines for Lynch syndrome and early detection can be
found via website: http://ghr.nlm.nih.gov/condition/lynch-syndrome. We are of opinion that
women diagnosed with Lynch syndrome should be counseled on and consider the prophy‐
lactic long-term use of a LNG-IUS in relation to their increased endometrial cancer risk.
2.5. Tamoxifen adjuvant treatment for breast cancer
The long-term recurrence and mortality rates of breast cancer have been substantially reduced
due to adjuvant treatment with tamoxifen. Tamoxifen is a selective estrogen receptor modu‐
lator (see Table 1) which exerts an anti-estrogenic effect on mammary tissue. [35] However, it
also induces endometrial proliferation and women using tamoxifen harbor significantly more
endometrial polyps than other women of which up to 36% could have hyperplasia or cancer.
[36] The prophylactic use of LNG-IUS in women with breast cancer treated with tamoxifen is
still controversial as the effect of the progestin released from the device on breast cancer
recurrence remains uncertain notwithstanding the significantly reduced incidence of endo‐
metrial polyps. [37] Nonetheless, in the future, this situation could be clarified by the advent
of an intrauterine system impregnated with a selective progesterone receptor modulator
(SPRM; see Table 2) that would demonstrate powerful progestin action on the endometrium
without any stimulatory, if not purely inhibitory, properties with regards to hormonally
sensitive breast glandular tissue.
Compound Commercial name(s) Principal indication(s)
Clomiphene Clomid, Clomifen Ovulation induction
Tamoxifen Tamoxiphene, Nolvadex Breast cancer
Raloxifene Evista Breast cancer, osteoporosis
DT56a Femarelle, Tofupill Menopause, osteoporosis
Table 1. Examples of selective estrogen receptor modulators, or SERMs, for the use in the clinical setting.
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Compound Commercial names Principal indications
Ulipristal Ella, ellaOne, Esmya Emergency contraception,
uterine leiomyomas
Asoprisnil (J867) Investigational
- no commercial name given
Uterine leiomyomas,
endometriosis
Telapristone (CDB-4124) Investigational
- bears names: Progenta, Proellex
Uterine leiomyomas,
endometriosis
Table 2. Examples of selective progesterone receptor modulators, or SPRMs, for the use in the clinical setting.
3. Biology of progesterone and progestins
The endometrium is highly sensitive to sex steroid hormones. Estrogens cause endometrial
proliferation and progesterone inhibits this growth by converting the endometrium to its
secretory stage to prepare the uterus for implantation. In relation to endometrial protection,
progesterone is the key inhibitor of carcinogenesis. The balance between the estrogen and
progesterone activity during the menstrual cycle must be precisely maintained as an increase
in the estrogen activity and/or a reduction in the antagonistic activity by progesterone will
stimulate carcinogenesis. Estrogens act upon the endometrium through estrogen receptors
(ERs), resulting in the induction of growth factors such as the epidermal growth factor, insulin-
like growth factor-1 and growth-enhancing protooncogenes c-fos and c-myc. Besides these
genomic effects of estrogens in the endometrium, estrogens exert nongenomic effects via
activation of the PI3K/Akt prosurvival signaling pathway. Progesterone acts by binding to
progesterone receptors (PRs), thus regulating multiple signaling pathways through PR-
dependent transcriptional activity. In addition to ligand-mediated regulation, PR activity is
also modulated by a variety of factors including microRNAs and epigenetic factors. [38]
Despite their high degree of sequence identity, the PR isoforms maintain a number of unique
biological functions, including: differences in transcriptional activity, ligand response, gene
regulation, and tissue-specific physiological effects. [39] Unbeneficial role of some progestins
is highlighted by the finding that medroxyprogesterone acetate, a widely used and quite
powerful progestin, stimulates vascular thrombin receptor in vitro, thus being capable of
triggering thromboembolic events. [40, 41]
4. Biology of progesterone receptor antagonists ― Potentially stronger
acting compounds?
Following the discovery of the antiprogestin mifepristone, hundreds of similar compounds
have been synthesized, which can be grouped in a large family of PR ligands. This family
includes pure agonists, such as progesterone itself and progestins, and, at the other end of the
biological spectrum, pure progesterone antagonists (PAs). An intermediate position of the
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spectrum is occupied by SPRMs which demonstrate mixed agonist–antagonist properties.
These compounds have numerous applications in healthcare of women.
Most PAs and SPRMs display direct antiproliferative effects in the endometrium when given
orally, although with variable strength being compound- and dose-dependent. PAs can also
be released using an IUS and induce endometrial atrophy in nonhuman primates. PAs and
SPRMs have two important effects in primates: 1) they suppress endometrial growth by
blocking the action of progesterone on endometrial progestational development and conse‐
quently induce amenorrhea; and 2) they suppress the proliferative effects of estrogen on
endometrial proliferation and prevent unopposed action on this tissue. [42] These properties
indicate the potential for clinical applications of these compounds which cover a broad field
and are very promising in major public health areas. These include emergency contraception,
long-term estrogen-free contraception (administered alone, or in association with a progestin-
only pill to improve bleeding patterns), uterine leiomyomas (where they induce a marked
reduction in tumor volume and produce amenorrhea) and endometriosis. Further develop‐
ments might also include the treatment of hormone-dependent tumors. [43, 44]
5. Rationale for prevention using levonorgestrel-releasing intrauterine
system
The first beneficial results with frameless FibroPlant® (Contrel Research, Ghent, Belgium)
LNG-IUS in women with non-atypical and atypical endometrial hyperplasia were published
in 2003. [45] Later, several reports followed using the framed Femilis® (Contrel Research) LNG-
IUS and included two cases of endometrial carcinoma, all successfully managed. [46, 47] No
failures occurred during follow-up for many years. The numbers were small but indicative of
the extraordinary impact of LNG to suppress the hyperplastic and atypical endometrium.
The risk of developing cancer in women with atypical endometrial hyperplasia untreated
for  20  years  is  between  8.6  and  42.5%.  [48]  In  contrast,  less  than  5%  of  women  with
nonatypical endometrial hyperplasia will experience progression to carcinoma. The lower
risk for women with nonatypical than atypical hyperplasia can assist in decision making
for  nonsurgical  management  of  endometrial  hyperplasia.  The  higher  risks  with  atypical
hyperplasia progressing to carcinoma warrant consideration of appropriate approaches as
concurrent carcinoma among patients with atypical endometrial hyperplasia can range from
17 to 52% across studies. [49]
The standard treatment for endometrial hyperplasia with atypia or early stage (pT1a) adeno‐
carcinoma of the endometrium is staging hysterectomy with bilateral oophorectomy. It is
rather clear that for many young women who wish to preserve their fertility, such a decision
is unacceptable. Studies using LNG-IUS releasing 20 μg of LNG/day indicate that successful
treatment is possible especially when such potent progestins as LNG are administered.
Intrauterine route of delivery appears much more effective than oral administration. [50, 51,
52] Successful treatment of early endometrial carcinoma has been reported with a 65 μg/day
progesterone-releasing IUS, followed up to 36 months, yet, results of biopsies were negative
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only in 7 of 11 at 6 months and 6 of 8 at 12 months. [8] A significant reduction of the ERs and
PRs expression observed during treatment with the LNG-IUS appears to be a marker for the
strong antiproliferative effect of the hormone at the cellular level. Furthermore, as the treat‐
ment is continuous, compliance is not an issue.
The most common source of endogenous unopposed estrogen is chronic anovulation which
can be accompanied by either continued ovarian secretion of estradiol or conversion of
circulating androstenedione and testosterone to estrone and estradiol, respectively, by
aromatase in the adipocytes. Chronic anovulation is a feature of PCOS and is also a condition
occurring frequently in the perimenopause. In all these women, whether they have a hyper‐
plastic condition due to exogenous or endogenous excess estrogen, direct delivery of LNG to
the target cells of the endometrium using an intrauterine device will cause substantial
histologic changes. The result is usually a very uniform suppression of the endometrium,
regardless of the duration of treatment, the histologic picture being independent of the distance
from the delivery system. [53] Intrauterine progestin delivery, particularly LNG, is therefore
probably the most effective intervention in preventing endometrial proliferation because of
the uniform suppression of the endometrium throughout the whole thickness of the mucosa
caused by the high tissue concentrations of the locally applied hormone. With oral progestin
therapy, a higher rate of residual hyperplasia, including complex and atypical hyperplasia,
has been observed. [54] It has been demonstrated that the duration of the progestin adminis‐
tration is more important than the daily dose for prevention of endometrial hyperplasia. Again,
continuous intrauterine progestin delivery seems optimal. [55]
Over the past 5 to 10 years many reports on the management of atypical endometrial hyper‐
plasia and early cancer of the endometrium with LNG-IUS have been published. [56-63]
Remissions were frequent, but also failures occurred. Some consider that at present there is no
sufficient evidence because most studies were underpowered or contained a high proportion
of patients lost to follow-up. [64] A meta-analysis and systematic review of the literature
concludes that the available evidence suggests that treatment with oral or intrauterine
progestin are of comparable effectiveness. The risk of progression during treatment is small,
but longer follow-up is required. [65] As recently highlighted by Scarselli et al., who followed
patients for over 15 years, LNG-IUS represents an option to treat hyperplasia and prevent
endometrial carcinoma in at least 85% of patients. [66] Consistent with that study, in order to
support stable regression over long periods of time, we recommend continued preventive
LNG-IUS use on a life-long basis using a suitable LNG-IUS as the uterine cavity is often very
small. Annual assessment of the endometrial thickness by ultrasound is probably sufficient
unless vaginal bleeding occurs.
6. Concluding remarks ― The future
Endometrial cancer is the fourth most common malignancy in women. Many women die each
year of this potentially preventive disease. Uterine precancerous conditions and even early
endometrioid cancer of the endometrium have a reasonably studied potential to respond to
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hormonal therapy. A growing body of evidence suggests that progestin therapy by means of
local long-acting release of a potent progestin can promote early endometrial tumor regression
and long-term remission.
Conservative management with LNG-IUS of precancerous changes and early well differen‐
tiated endometrial cancer seems particularly promising in women who wish to preserve
their fertility. It is emerging as an alternative to oral progestins as higher regression and
lower hysterectomy rates for the treatment of complex and atypical hyperplasia are achieved
with  the  device.  LNG-IUS  should,  therefore,  be  the  first-line  primary  prevention  treat‐
ment.  [67-75]  However,  conservative  treatment  carries  an  inherent  oncologic  risk  as  no
correct staging is possible and the risk of missing a concurrent ovarian cancer cannot be
neglected.  Pre-treatment  evaluation  should  include  assessment  for  genetic  conditions
predisposing to cancer, such as Lynch syndrome. It is apparent that the ideal candidates
for  conservative  cancer  treatment  are  young women with  grade 1,  early  stage  endome‐
trioid  endometrial  cancer  (T1)  with  no  detectable  myometrial  invasion  who  are  highly
motivated to maintain their reproductive potential and understand and are willing to accept
the risk associated with deviation from the established standard of care. [59, 76] Proges‐
tins rather than progesterone should be considered the ultimate tumor suppressors as they
powerfully promote differentiation, cell cycle arrest and apoptosis, and reduce inflamma‐
tion and the invasion associated with metastasis. [37] Patients in whom the treatment fails
should be evaluated by immunochemistry on endometrial biopsies as treatment failure is
often caused by loss of PR expression. Clinical research is currently underway focusing on
maintaining PR levels or identifying novel therapeutic approaches that restore PR expres‐
sion in tumors from which it has been lost. [38, 77] Failure could also occur simply due to
the downward displacement of  the hormone-releasing IUS causing less  impact  on areas
away  from  the  IUS.  Proper  distribution  of  the  hormone  to  the  deeper  layers  of  the
endometrium seems essential to achieve maximum impact.
As the lifetime risk of endometrial cancer in anovulating obese women is 15% or more, one
could assume that many of these cancers could be prevented using LNG-IUS. We support such
an approach together with others who believe that it could be successful provided that suitable
LNG-releasing intrauterine delivery systems are used. The latter is important as the uterine
cavities in women of any age are often small and even become smaller with the use of LNG-
IUS. Side effects such as displacement, embedment and expulsion are not rare, leading to early
discontinuation. [78] Leslie at al. hope that the following will be possible in the future: “As a
profession, we should ask ourselves if we can not only treat, but prevent a substantial
proportion of endometrial cancers with more liberal use of progestin-containing IUDs?” [79]
Apart from the emerging role of LNG-IUS for endometrial cancer prevention, as reviewed
recently by Jóźwik et al. [80], the future might lead us to even more effective hormone-releasing
IUDs. It was proposed that local delivery of other drugs such as mifepristone or ulipristal, with
their strong antiprogestin activity and antiestrogenic effect at the endometrial level, may be
more suitable than LNG to act as tumor suppressor. No studies with intrauterine delivery of
these agents have been conducted so far. However, one example is worth mentioning which
indicates the potential of these compounds: A 48-year old nulliparous woman was consulted
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by one of the authors (DW) in 2007 for bleeding problems. It was known that she suffered from
multiple uterine leiomyomas which tended to increase in size significantly over the past years.
A pipelle biopsy revealed atypical hyperplasia. On MRI, the uterus was increased in size with
several leiomyomas, the largest being of 65 mm in diameter. A frameless mifepristone-
releasing IUS was inserted on 20 January 2007. The first follow-up was done one month later.
At that time, the patient mentioned some spotting and a repeat biopsy showed residual focal
atypical hyperplasia. Three months after insertion, breakthrough bleeding stopped complete‐
ly, the diameter of the largest myoma was reduced to 33 mm and a histological specimen
showed deficient endometrium without signs of atypia. All further follow-up examinations
were uneventful with no abnormal bleeding. The patient was kept on this experimental
mifepristone-releasing IUS for approximately 5 years. It was replaced by a LNG-IUS at the end
of 2011 and, at annual check-ups, she has remained asymptomatic.
Finally, it is worth mentioning that several large epidemiological studies pointed out the
potential of metformin as an anticancer drug. Metformin is an oral antidiabetic drug and is the
first-line drug for the treatment of type 2 diabetes, in particular, in overweight and obese
subjects with normal kidney function. It is used for the treatment of PCOS and has been
investigated for other diseases where insulin resistance seems an important factor. Metformin
acts by suppressing glucose production in the liver and has a vast safety track record. Preclin‐
ical and early clinical trials suggest a role for metformin in the prevention and treatment of
cancer. Its potential is still unproven, but seems extremely promising. [81] Recently, a phase 2
study was designed in Australia combining LNG-IUS with oral metformin for the treatment
of complex endometrial hyperplasia with atypia and grade 1 endometrial endometrioid
adenocarcinoma. [82] Hopefully, this and other careful clinical studies will path a new
approach to the prevention and treatment of early endometrial cancer.
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